Related Experiment Videos
Technology evaluation: cintredekin besudotox, NeoPharm/Nippon
Nikolai G Rainov1, Ariane Söling
1University of Liverpool, Department of Neurological Science, The Walton Centre for Neurology and Neurosurgery NHS Trust, Lower Lane, Liverpool L9 7LJ, UK. N.G.Rainov@liverpool.ac.uk
Current Opinion in Molecular Therapeutics
|April 23, 2005
Summary
NeoPharm is developing cintredekin besudotox, an antitumor agent, for cancer treatment. This chimeric protein is currently in phase III clinical trials to evaluate its efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Developing novel antitumor agents is crucial for improving cancer patient outcomes.
- Targeted therapies offer potential for increased efficacy and reduced side effects.
- Chimeric proteins combining targeting ligands with cytotoxic payloads represent a promising therapeutic strategy.
Purpose of the Study:
- To evaluate the potential of cintredekin besudotox as an antitumor agent.
- To assess the safety and efficacy of cintredekin besudotox in ongoing clinical trials.
Main Methods:
- Cintredekin besudotox is a chimeric protein comprising a human IL-13 targeting moiety and a Pseudomonas exotoxin cytotoxic payload.
- Development is conducted by NeoPharm Inc., under license from NIH and FDA, in collaboration with Nippon Kayaku Co Ltd.
- The agent is currently undergoing phase III clinical trials.
Main Results:
- Phase III clinical trials are in progress to determine the antitumor activity of cintredekin besudotox.
- Data from ongoing trials will elucidate the efficacy and safety profile of this novel therapeutic agent.
Conclusions:
- Cintredekin besudotox shows promise as a targeted antitumor agent.
- Further results from phase III trials are anticipated to confirm its clinical utility in cancer therapy.